<DOC>
	<DOCNO>NCT01606436</DOCNO>
	<brief_summary>This study determine single dose pomaglumetad methionil affect electrical activity heart people schizophrenia . This study also help determine single high dose pomaglumetad methionil tolerate participant .</brief_summary>
	<brief_title>A Study Measuring Effect Pomaglumetad Methionil ( LY2140023 ) Electrocardiographs Participants With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Diagnosis schizophrenia Female participant postmenopausal Not hospitalize psychiatric illness least 12 week prior Day 1 study Willing able hospitalize Day 1 end study Can wash antipsychotic medication duration study Considered reliable , able understand , willing perform study procedure Understand nature study give write informed consent Clinical laboratory test result within normal reference range Venous access sufficient allow blood sample Clinically acceptable sit blood pressure heart rate Currently enrol , complete discontinue within last 30 day clinical trial involve investigational drug Known allergy pomaglumetad methionil active metabolite ( LY404039 ) , moxifloxacin , related compound component Previously complete study prematurely discontinue study receive least 1 dose pomaglumetad methionil Received treatment clozapine Received aripiprazole within 2 month prior screen Taking either thioridazine thiothixene Receiving treatment depot antipsychotic medication within 12 week , prior screen Taking medication specifically permit protocol Asthma need active beta 2 ( B2 ) agonist within 14 day study Active suicidal ideation intent act , without specific plan specific plan intent OR suicidal behavior actual attempt , interrupt attempt , abort attempt , preparatory act behavior within past 3 month Substance dependence substance abuse ( except nicotine caffeine ) within 6 month prior admission Substanceinduced psychosis within 7 day admission ( time dose period ) History 1 seizure ( exception ) Screening electroencephalogram ( EEG ) paroxysmal ( epileptiform ) activity Have electroconvulsive therapy ( ECT ) within 3 month Day 1 study expect ECT time live phase study Parkinson 's disease , dementiarelated psychosis , related disorder Untreated hyperthyroidism hypothyroidism need thyroid hormone supplement stable dose medication least 2 month prior screen History leukopenia agranulocytosis Alanine aminotransferase/serum glutamic pyruvic transaminase ( ALT/SGPT ) aspartate aminotransferase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) value great 2 time upper limit normal ( ULN ) total bilirubin value great 1.5 time ULN perform laboratory screen Abnormality 12lead electrocardiogram ( ECG ) increase risk associate participate study Premature ventricular contraction ( PVC ) associate symptoms and/or complex PVCs Heart rhythm disturbance history ECG screen Personal family history long Q wave T wave ( QT ) syndrome Family history sudden unexplained death cardiac death family member 60 year age Unexplained syncope within last year Acute , serious , unstable medical condition Prolactin level great 200 nanogram per milliliter ( ng/mL ) ( 200 microgram per liter [ ug/L ] , 4228 milliinternational unit per liter [ mIU/L ] ) screening ( exception participant treat risperidone ) screen Medical history Human Immunodeficiency Virus positive ( HIV+ ) status Test positive ( 1 ) Hepatitis C virus antibody ( 2 ) Hepatitis B surface antigen ( HBsAg ) without positive Hepatitis B core total antibody Smoke great equal 40 cigarette per day Movement disorder could interfere conduct 12lead ECGs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>